AltrixBio Secures Funding to Propel Clinical Advancements
- Current CEO and Co-founder Nancy Briefs Transitions to Executive Chair of the Board -
- Financing and Leadership Transition Strengthen Momentum Toward First Clinical Trial of AJN 003 for Type 2 Diabetes -
AltrixBio, a biopharmaceutical firm focused on innovating treatments for cardiometabolic diseases, has successfully closed a substantial $5 million Series A financing. This investment is pivotal for hastening the clinical development of AJN 003 (LuCI™ - Luminal Coating of the Intestine), an oral therapeutic solution designed to reform the management of type 2 diabetes and related metabolic disorders.
In conjunction with this exciting financial development, the company has appointed David Pass, PharmD, as the new president and chief executive officer. Dr. Pass is a seasoned leader with extensive experience across pharmaceuticals, biotechnology, and medical devices, having successfully guided initiatives from conception to acquisitions surpassing $1 billion in sales. He takes over from AltrixBio Co-founder and CEO Nancy Briefs, who will now serve as the executive chair of the board after her dedicated leadership from the company’s inception.
Dr. Pass expressed enthusiasm about joining AltrixBio during such a significant phase, stating, "I am inspired by the potential of AJN 003 both to change the way we think about the science of type 2 diabetes and metabolic disorders, and to bring the often life-changing benefits of bariatric surgery into a pill." His ambition is to usher the company into a new era of clinical and operational success.
Innovative Approach of AJN 003
AJN 003 is being developed as a once-daily oral administration designed to imitate the metabolic effects of bariatric surgery, which has shown to result in quick improvements in glucose regulation and even remission of diabetes in many patients, coupled with noteworthy weight reduction. By using AJN 003, AltrixBio aims to harness these benefits while minimizing the risks associated with surgical procedures.
Preclinical evaluations of AJN 003 have indicated its ability to induce similar hormonal and metabolic responses. The funding acquired through Series A will play a crucial role in propelling AJN 003 into human clinical trials, with the goal of delivering an effective oral treatment option for those grappling with type 2 diabetes, obesity, and various other metabolic health issues. This inventive treatment provides vast commercial opportunities on a global scale.
Leadership Transition and Future Direction
The elevation of Dr. Pass to CEO not only signifies a leadership transition but also indicates the commencement of a new chapter for AltrixBio. His past successes in managing the Diabetes Franchise as well as his previous role as president of Life Sciences at Glooko underline his capacity to drive the company's mission forward.
Nancy Briefs commented, "I am proud of our collective achievements and am looking forward to continuing my support for AltrixBio as executive chair of the board." She further emphasized Dr. Pass's appointment as an element reflecting the commitment to maintain high standards of leadership and long-term business success.
Ali Tavakkoli, MD, co-founder and board member, also weighed in, expressing gratitude for Ms. Briefs’ insightful guidance and welcome to Dr. Pass. His specialist knowledge and keen enthusiasm for AltrixBio's mission are expected to be crucial as the company formulates its vision of delivering innovative approaches such as 'Surgery in a Pill®'.
Understanding AJN 003 (LuCI™)
AJN 003 is a groundbreaking oral therapy that creates a temporary lining in the gastrointestinal tract, particularly in the stomach, duodenum, and jejunum, enabling it to replicate the metabolic advantages of bariatric bypass surgery. Emerging research shows that AJN 003 modifies the way nutrients are sensed in these regions, triggering similar hormonal and metabolic responses. With this novel small molecule therapy, the goal is to provide a promising avenue for tackling type 2 diabetes and its associated metabolic complications.
About AltrixBio
Founded in 2019, AltrixBio is built on work originating from scholars such as Jeff Karp, PhD, and Ali Tavakkoli, MD, associated with academic institutions driving innovative biopharmaceutical advancements. Their research has taken inspiration from rapid health improvements observed in patients post-bariatric surgery. The company seeks to transform established treatments into more adaptable and less invasive therapeutic options, epitomized by AJN 003.
Frequently Asked Questions
What is AltrixBio's primary focus?
AltrixBio specializes in developing pioneering treatments for cardiometabolic diseases, particularly focusing on type 2 diabetes management.
Who is the newly appointed CEO?
David Pass, PharmD, has been appointed as the new CEO, bringing extensive leadership experience in the healthcare sector.
What is AJN 003?
AJN 003 is a novel oral therapy designed to mimic the benefits of bariatric surgery by temporarily coating parts of the digestive tract to enhance metabolic health.
What funding has AltrixBio recently secured?
AltrixBio has closed a $5 million Series A financing to expedite the clinical development of AJN 003.
What does the leadership transition mean for AltrixBio?
The leadership transition is a strategic move intended to invigorate the company's approach toward clinical and commercial undertakings, ensuring continued growth and innovation.
